Based on multiple clinical and preclinical studies demonstrating an association between altered peripheral Gal-3 levels and interstitial fibrosis and inflammation, with consequent organ (mainly heart and lung) failure [35–37], in the 2017 guidelines, the American Heart Association recommended Gal-3 measurement for the prognosis of HF [38], and circulating Gal-3 levels were suggested as biomarkers of cardiovascular diseases (CVDs) and non-CVDs [39–41]. This evidence concerns the gene LGALS3 and cardiovascular disorder.